←
Translational Cancer Epigenomics228 posts
Translational Cancer Epigenomics avatar

Translational Cancer Epigenomics

@TransCanEpi

Official account Section Translational Cancer Epigenomics @TMO_Heidelberg @NCT_HD @DKFZ, #epigenomics, #hematopoiesis, #JMML, #singleCell, #precisiononcology

◷ Joined June 2022▧ 7 Photos and videos
Daniel Lipka avatar
⟳ Translational Cancer Epigenomics retweeted
Daniel Lipka@dblipka1·Jul 6

‼️ Pre-print alert from the Lipka lab ‼️ Our latest work “Hierarchical classification of hematologic malignancies using epigenetic and genetic information” is now online! biorxiv.org/content/10.64898… Thanks to all colleagues who contributed to this work! 🙏

Ofir Cohn avatar
⟳ Translational Cancer Epigenomics retweeted
Ofir Cohn@CohnOfir·Jun 2

Decades of research have revealed the intricacies of how dendritic cells (DCs) function, but fundamental questions remain about how this group of cells develops in humans and how this process goes awry in disease. A thread on our new work! (1/9) biorxiv.org/content/10.64898…

Post attachment
Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

13/ Huge congratulations to first author @MariamHakobya20 and all collaborators and a big THANK YOU for all your efforts and support throughout the project! 🎉 📄 Paper link 👇 doi.org/10.1182/blood.202503… #AML #Leukemia #IDH1 #Epigenetics #Hematology #BloodCancer @DKFZ @NCT_HD

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

12/ To summarise: → IDH1 is highly expressed in myeloid progenitors (unlike IDH2) → Mutant IDH1 epigenetically silences Cebpe → neutrophil block → The block persists after IDH1 inhibition alone → IDH1i + hypomethylating agent fully rescues the defect

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

11/ The efficacy of combined IDH1i + Aza mirrors the superior outcomes seen with ivosidenib + Aza in the AGILE trial — and now we have a mechanistic explanation for why it works.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

10/ 🔬The winning combination: IDH1 inhibitor + 5-azacitidine. This erased aberrant DNA methylation at the Cebpe locus, restored expression, and fully rescued neutrophil differentiation.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

9/ Great news: the differentiation block is reversible! ✅ Forcing CEBPE activation fully rescued neutrophil differentiation. ⚠️ IDH1 inhibition (AGI-5198) alone? It cleared D2HG and restored proliferation — yet Cebpe silencing and the neutrophil defect persisted.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

7/ What's the molecular mechanism? Single-cell & bulk transcriptomics of Idh1-R132H neutrophil progenitors pointed to impaired activation of Cebpe 🎯 A master transcription factor for terminal neutrophil maturation, which fails to be activated in mutant progenitors.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

6/ To study this mechanistically, we used a heterozygous Idh1-R132H mouse model under the control of the endogenous promoter. Result: a clear, cell-intrinsic block in neutrophil differentiation with accumulation of myeloid progenitors and reduction in mature neutrophils

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

5/ This expression pattern is epigenetically regulated. A specific Idh1 transcript variant shows progressive DNA demethylation at its TSS specifically in the myeloid lineage — meaning myeloid progenitors are uniquely primed to express IDH1 at high levels.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

4/ 🤔But why would IDH1 mutations specifically affect neutrophils? Using single-cell RNA-seq data from human + mouse bone marrow, we found that IDH1 is strongly upregulated in myeloid progenitors, while IDH2 was expressed more homogeneously across all lineages.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

3/ This epigenetic clue had a clear clinical correlate. Across ~4,000 AML patients, IDH1-mutant patients had: 🔻 Significantly less bone marrow granulopoiesis 🔻 Lower absolute neutrophil counts in blood …compared to both IDH2-mutant and other AML subtypes.

Translational Cancer Epigenomics avatar
Translational Cancer Epigenomics@TransCanEpi·May 29

2/ We started by asking: do IDH1- and IDH2-mutant AMLs look different at the DNA methylation level? Analysing 473 AML patients, we found that IDH1-mutant — but not IDH2-mutant — AMLs carry an epigenetic "scar" from the neutrophil differentiation program.